The search for a cure starts with your DNA.
Learn about 23andMe's commitment to Parkinson's research and how you can participate.
Inside all of us is the power to advance Parkinson's research through our genetics.
We are excited to join The Michael J. Fox Foundation for Parkinson's Research (MJFF) as a partner on Fox Insight, an online study designed to collect data from Parkinson's patients to inform research and drug development. MJFF is the largest non-profit funder of Parkinson's research and shares our goal of revolutionizing Parkinson's research through genetics.
When you join Fox Insight, you may be eligible to participate in the Fox Insight Genetic Sub-study powered by 23andMe. You could make a difference.
The power to effect change increases with the number of people participating in research and with greater amounts of data for researchers to mine and analyze.
At 23andMe, we believe genetic data will play a critical role in Parkinson's research.
Our commitment to Parkinson's research is in our DNA.
The power to effect change increases with the number of people participating in research and with greater amounts of data for researchers to mine and analyze.
Since 2006, 23andMe has been the world's leading personal genetics company. In 2009, we launched the world's largest genetic study of Parkinson's disease (PD), now more than 11,000 participants strong.
In the beginning, we wanted more answers. We wanted to contribute to research and better understand the impact genetics has on this disease.
So, we launched a new kind of research. One that uses the web to bring people together to share their personal health and genetic data with researchers — regardless of how close they live to a clinic or research facility.
Today our commitment to accelerating and advancing PD research is stronger than ever. We believe understanding more about how our genetics influences this disease should improve diagnosis and treatment, and may eventually lead to a cure. That is our goal.
“What 23andMe did in a matter of years would have taken several decades and tens of millions of dollars if done conventionally.”
Haydeh Payami, New York State Department of Health
Together, with our research participants and partners, we've made an impact.
“What 23andMe did in a matter of years would have taken several decades and tens of millions of dollars if done conventionally.”
Haydeh Payami, New York State Department of Health
-
2009
We launched the unprecedented web-based Parkinson's Research Community. Within six months, we had the largest genetic research cohort in the world.
-
2011
After 2 years, 23andMe found two new genetic associations with Parkinson's, providing new evidence that there is a substantial genetic component still to be discovered for PD.
-
2012
We contributed to a new database that created the most comprehensive synopsis of Parkinson's disease genetic research to date.
-
2013
- We contributed to a study whose preliminary findings suggest that increased iron levels are associated with a decreased risk of PD.
- We launched a study on the LRRK2 genetic mutation in collaboration with The Michael J. Fox Foundation for Parkinson's Research.
-
2014
Working as part of a broader research group, 23andMe identified six new genetic regions that had not previously been associated with Parkinson's disease.
-
2015
We partnered with global pharma company Genentech to identify new drug targets and therapies by analyzing the complete DNA makeup (whole genome sequence data) of approximately 3,000 23andMe research participants.
-
2017
23andMe collaborated with The Michael J. Fox Foundation for Parkinson's Research to enable genetic data collection and sharing with qualified researchers through the Fox Insight Genetic Sub-study.
Some of the amazing people who have contributed to our PD research over the years.
-
The Parkinson's disease community lost a truly inspirational leader with the passing of Muhammad Ali on June 7, 2016. -
Claudia shares her story of living with Parkinson's disease and why she believes participating in genetic research is so important.
FAQ
Hi. Still have questions about 23andMe and PD Research? If you don't see your question here, get in touch with us.
-
What is the Fox Insight Genetic Sub-Study?
Fox Insight is a Michael J. Fox Foundation for Parkinson's Research online study to gather the world's largest collection of data about life with Parkinson's. 23andMe and The Michael J. Fox Foundation are joining together to launch a sub-study to add genetics to the information collected through Fox Insight.
The goal of the Fox Insight Genetic Sub-Study is to accelerate PD research through a large, longitudinal study combining genetics and patient reported data. Genetic data from the sub-study will be shared broadly to researchers studying PD.
Eligible Fox Insight participants will be invited to participate in the Fox Insight Genetic Sub-Study. Learn more about Fox Insight here.
-
Who can I contact if I have more questions about Fox Insight?
For questions regarding Fox Insight, please contact info@foxinsight.org.
-
Is the 23andMe Parkinson's research initiative still enrolling participants?
Enrollment in the 23andMe Parkinson's research initiative is now closed. Thank you to all the community members who made this PD research possible.
23andMe will continue to analyze data from community members and will inform community members if future opportunities to participate in PD research are available.
-
Who can I contact if I have more questions about the 23andMe Parkinson's research initiative?
For questions regarding this research initiative or your 23andMe account, please contact pd-help@23andme.com.